Keith Marcus
Ann Arbor, MINPI 1093831604
Payments from drug & device makers
Across 804 payments — averaging $1334.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$530K
- AbbVie$485K
- Merz North America, Inc.$58K
- Revance Therapeutics, Inc.$419
- Endo Pharmaceuticals Inc.$68
- Solta Medical, A Division Of Bausch Health US, LLC$17
Across 13 payments — averaging $17,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$226K
- AbbVie$506
What the payments were for
- Consulting fees$196,37622%
- Speaking & faculty fees$600,94968%
- Travel & lodging$59,0557%
- Food & beverage$23,7723%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 292 | $529,832 |
| AbbVie(2 entities) | 395 | $484,610 |
| Merz North America, Inc. | 108 | $58,291 |
| Revance Therapeutics, Inc. | 7 | $419 |
| Endo Pharmaceuticals Inc. | 1 | $68 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.